Key facts
- Notable investors include Oost NL, Horizon 2020, Horizon Europe, LifeSciences@Work.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Mercurna
- ·The full record, as it builds
Funding rounds
No funding rounds for Mercurna are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mercurna
Developer of mRNA-based medicines intended to combine unique cell-targeting ligands with a proprietary lipid-based delivery vehicle to deliver engineered mRNA with high efficiency and high specificity to the diseased tissues. The company's technology delivers novel formulations to targeted cells to treat chronic inflammatory diseases in the kidney and other organs, enabling customers to have precision medicines for eye disease, gum disease, chronic kidney disease, sepsis, and skin and lung diseases.
- Sector
- Healthcare
- HQ
- Nijmegen, Netherlands
- Employees
- 9
- Website
- mercurna.com/
- Ownership
- Privately Held (backing)
Mercurna doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mercurna shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mercurna in its N-PORT filings yet. We sweep new filings monthly.